RNA Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TransCode Therapeutics has appointed Dr. Phillip D. Zamore, a leading RNAi researcher, to its Scientific Advisory Board, potentially strengthening the company's oncology research capabilities and RNA therapeutic development strategies.
TransCode Therapeutics has strategically enhanced its scientific leadership by appointing Dr. Phillip D. Zamore to its Scientific Advisory Board. As a renowned expert in RNA interference (RNAi) research and co-founder of Alnylam Pharmaceuticals, Zamore brings significant expertise to the clinical-stage oncology company.
Dr. Zamore, who currently serves as Chair of the RNA Therapeutics Institute at UMass Chan Medical School, is a distinguished scientist recognized for his foundational work in RNA biology and gene silencing mechanisms. His election to the National Academy of Sciences underscores his substantial contributions to the field of molecular biology.
The appointment comes as TransCode focuses on developing RNA therapeutics targeting metastatic cancers, with its lead candidate TTX-MC138 designed to treat tumors overexpressing microRNA-10b. Zamore's expertise in RNA mechanisms could potentially accelerate the company's research and development efforts in developing innovative cancer treatments.
By bringing a leading RNAi pioneer onto its Scientific Advisory Board, TransCode signals its commitment to advancing cutting-edge RNA therapeutic technologies. Zamore's deep understanding of RNA biology and gene silencing could provide critical insights that help overcome existing challenges in RNA delivery and therapeutic targeting.